In 52 overweight or obese adults with schizophrenia spectrum disorders on atypical antipsychotics, 16 weeks of empagliflozin plus lifestyle intervention reduced body weight (-1.53 kg) and BMI (-0.53 kg/m2) versus placebo; adverse events and dropouts were similar.
RCTn = 52
Wong et al. Effects of Empagliflozin and Lifestyle Intervention on Improving Body Weight and Other Metabolic Parameters in Atypical Antipsychotics-treated Patients with Schizophrenia Spectrum Disorders-A Double-blind Randomized Placebo-controlled Trial